

## Non-clinical study of VRN11, a CNS-penetrable inhibitor for EGFRG719X, L861X, S768I/V as well as C797S mutation NSCLC patients

VORONOI, Inc.

ONCOLOGY	Pre-Clinical
Product Type	Small Molecule (kinase inhibitor)
Indication	Non-Small Cell Lung Cancer (NSCLC)
Target	EGFR mutations
MoA(Mechanism of Action)	Prevent cancer proliferation by inhibiting kinase activity of EGFR mutations
Competitiveness	Blueprint Medicines BLU-525, IND enabling Bridgebio Therapeutics BBT-207, IND enabling VRN11 is more brain permeable and EGFR WT sparing
Development Stage	Pre-Clinical
Route of Administration	Oral